(3S,6S)-4-(5-cyclopropylisoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one | 1391625-89-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S,6S)-4-(5-cyclopropylisoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one
• 英文别名: (3S,6S)-4-(5-cyclopropyl-1,2-oxazole-3-carbonyl)-3,6-bis(2-methylpropyl)piperazin-2-one
• CAS: 1391625-89-0
• 化学式: C₁₉H₂₉N₃O₃
• 分子量: 347.458
• InChiKey: KEMNSAOBYZPEAD-HOCLYGCPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  75.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (3S,6S)-3,6-diisobutyl-4-(4-phenoxybenzoyl)piperazin-2-one 、 (3S,6S)-3,6-diisobutylpiperazin-2-one 、 5-环丙基异噁唑-3-羧酸 以to give the product 106 (122.2 mg, 74.8% yield) as a yellow oil的产率得到(3S,6S)-4-(5-cyclopropylisoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one
  参考文献：
  名称：

  COMPOUNDS

  摘要：

  本文公开了用于治疗病毒感染，如HCV的化合物。

  公开号：

  US20120202794A1

文献信息

• [EN] PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C<br/>[FR] DÉRIVÉS DE PYRAZINE ET D'IMIDAZOLIDINE ET LEURS UTILISATIONS EN VUE DU TRAITEMENT DE L'HÉPATITE C
  申请人：GILEAD PHARMASSET LLC

  公开号：WO2012103113A1

  公开（公告）日：2012-08-02

  Disclosed herein are compounds useful for treating a viral infection, such HCV.

  本文披露了一些用于治疗病毒感染，如HCV的化合物。
• CYAA-CARRIED POLYPEPTIDE(S) AND USE TO INDUCE BOTH THERAPEUTIC AND PROPHYLACTIC IMMUNE RESPONSES
  申请人：Genticel

  公开号：EP2667890A1

  公开（公告）日：2013-12-04
• [EN] CYAA-CARRIED POLYPEPTIDE(S) AND USE TO INDUCE BOTH THERAPEUTIC AND PROPHYLACTIC IMMUNE RESPONSES<br/>[FR] POLYPEPTIDE(S) PORTÉ(S) PAR LA CYAA ET LEUR UTILISATION POUR INDUIRE À LA FOIS UNE RÉPONSE THÉRAPEUTIQUE ET UNE RÉPONSE IMMUNITAIRE PROPHYLACTIQUE
  申请人：GENTICEL

  公开号：WO2012101112A1

  公开（公告）日：2012-08-02

  The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s).